/Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
NEWS
Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
PRNewswire
2026/01/12Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel) News provided by Minaris Advanced Therapies Jan 12, 2026, 08:00 ET Share this article Share to X Share this article Share to X Minaris Genetix Biotherapeutics
Summary
Minaris expands commercial manufacturing for LYFGENIA™, a first-in-class FDA approved gene therapy for patients with sickle cell disease Expanded capacity meets growing patient demand while delivering improved manufacturing efficiency and accelerated treatment timelines for patients...